Verastem

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will participate in the virtual H.C. Wainwright Global Life Sciences Conference. The fireside chat will be made available for on-demand listening beginning Tuesday, March 9, 2021 at 7:00 a.m. EST. The webcast of the fireside chat will be available on the “Media” section of the Comp

Verastem Oncology to Participate in the H.C. Wainwright Global Life Sciences Conference

The biotech's chief medical officer has stepped down just two weeks after joining the company.

Why Verastem Stock Sank Today

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the departure of the Company's Chief Medical Officer, Frank Neumann, M.D., Ph.D., effective immediately. Dr. Neumann has left to accept a position at another Company. “Our team is making significant advances in achieving the Company's strategic goals, including maximizing the broad potential of our

Frank Neumann, M.D., Ph.D., to Depart Verastem Oncology

Verastem has recently raised non-dilutive capital to bring two assets into phase 2 trials. The company's lead asset has the potential to address around 30% of all cancers and be combined with other medicines.

Verastem Oncology: Targeting The RAS Pathway To Develop New Cancer Medicines

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of industry veteran Frank Neumann, M.D., Ph.D., as Chief Medical Officer to oversee the Company's clinical and regulatory strategy and Medical Affairs team. “Frank brings deep expertise across the full spectrum of clinical and regulatory activities in all stages of Oncology drug dev

Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the virtual H.C. Wainwright BioConnect 2021 Conference. The fireside chat will be made available for on-demand listening beginning Monday, January 11, 2021 at 6:00 a.m. EST. The webcast of the fireside chat will be available on the “Media” section of the Company's w

Verastem Oncology to Present at the H.C. Wainwright BioConnect 2021 Conference

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, alone and in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant non-small cell lung cancer (NSCLC). “Currently available options for patients with KRAS mutant NSCLC are asso

Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer

Verastem (VSTM) initiates phase II registration-directed study of VS-6766 and defactinib in patients with recurrent low-grade serous ovarian cancer.

Verastem (VSTM) Begins Phase II Combo Study for Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, and defactinib, its FAK inhibitor, in patients with recurrent low-grade serous ovarian cancer (LGSOC). “Results to date have demonstrated the clinical activity of VS-6766 and defactinib in KRAS mutan

Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported financial results for the three months ending September 30, 2020, and provided an overview of recent corporate highlights. “The third quarter of 2020 was marked most notably by the sale of the COPIKTRA (duvelisib) franchise to Secura Bio in a deal valued at up to $311 million, plus royalties. This s

Verastem Oncology Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced new data have been published today in The Lancet Oncology. The study evaluated the intermittent dosing schedule of VS-6766 (formerly known as CH5126766) to inform further testing of VS-6766 as both a single agent in RAS/RAF-mutant cancers such as KRAS mutant non-small cell lung cancer (NSCLC) or in

Verastem Oncology Announces New Data Published in The Lancet Oncology Supports Potential of VS-6766 as Treatment for RAS Mutant Tumors

Verastem (VSTM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Verastem (VSTM) Jumps: Stock Rises 7.1%

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that it has completed the sale of Verastem's COPIKTRA (duvelisib), a marketed oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first FDA-approved dual inhibitor of PI3K-delta and PI3K-gamma, to Secura Bio, Inc. In consideration for the COPIKTRA assets, Verastem received from Secura Bio $

Verastem Oncology Announces Closing of COPIKTRA® (duvelisib) Sale to Secura Bio

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced updated results from the ongoing investigator-initiated Phase 1/2 FRAME study evaluating VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, which demonstrated robust response rates, duration of response and a favorable safety profile in patients with low-grade serous

Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Verastem (VSTM) Stock?

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that management will host an investor conference call to discuss the updated clinical data from the low-grade serous ovarian cancer (LGSOC) cohort of the ongoing investigator-initiated Phase 1/2 FRAME study.

Verastem Oncology Announces Investor Conference Call to Discuss Updated Clinical Data in Low-Grade Serous Ovarian Cancer from Phase 1/2 FRAME Study

The biotech company reported second-quarter earnings and sold some drug development rights.

Why Verastem Stock Jumped Briefly This Morning

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today reported financial results for the three months ending June 30, 2020, and provided an overview of recent corporate highlights.

Verastem Oncology Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that it has entered into a definitive agreement to sell its global commercial and development rights to COPIKTRA (duvelisib), its marketed oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first FDA-approved dual inhibitor of PI3K-delta and PI3K-gamma, to Secura Bio, Inc.

Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA® (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors

Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Verastem (VSTM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Verastem: A Growth Story In The Biotechnology Sector

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced results from a study that provides preclinical proof-of-concept for combining VS-6766, its RAF/MEK inhibitor, with defactinib, its focal adhesion kinase (FAK) inhibitor, for the treatment of metastatic uveal melanoma (UM), the most prevalent eye cancer among adults. The data co

Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal Melanoma

Are Options Traders Betting on a Big Move in Verastem (VSTM) Stock?

If this biotech is ever going to reward its shareholders, it will be via its pipeline candidates.

Why Verastem Stock Is Rising Today

Is  (VSTM) Outperforming Other Medical Stocks This Year?

News for Verastem Stock (VSTM)